Menu
Search
|

Menu

Close
X

Sarepta Therapeutics Inc SRPT.OQ (NASDAQ Stock Exchange Global Select Market)

111.99 USD
-- (--)
As of Nov 14
chart
Previous Close 111.99
Open --
Volume --
3m Avg Volume 344,399
Today’s High --
Today’s Low --
52 Week High 176.44
52 Week Low 50.68
Shares Outstanding (mil) 66.82
Market Capitalization (mil) 7,803.00
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.65 Mean rating from 23 analysts

KEY STATS

Revenue (mm, USD)
FY18
217
FY17
155
FY16
5
FY15
1
EPS (USD)
FY18
-3.370
FY17
-0.798
FY16
-5.452
FY15
-5.192
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
28.49
22.95
Price to Book (MRQ)
vs sector
12.17
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
64.93
15.47
LT Debt to Equity (MRQ)
vs sector
64.93
11.13
Return on Investment (TTM)
vs sector
-27.25
13.00
Return on Equity (TTM)
vs sector
-36.65
14.69

EXECUTIVE LEADERSHIP

M. Kathleen Behrens
Independent Chairwoman of the Board, Since 2015
Salary: --
Bonus: --
Douglas Ingram
President, Chief Executive Officer, Director, Since 2017
Salary: $337,500.00
Bonus: $420,875.00
Sandesh Mahatme
Executive Vice President, Chief Financial Officer and Chief Business Officer, Since 2017
Salary: $459,252.00
Bonus: $257,181.00
Guriqbal Basi
Senior Vice President, Chief Scientific Officer, Since 2017
Salary: $105,000.00
Bonus: $72,800.00
David Howton
Senior Vice President, General Counsel, Corporate Secretary, Since 2012
Salary: $407,176.00
Bonus: $228,019.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

215 1st St Ste 415
CAMBRIDGE   MA   02142-1213

Phone: +1617.2744000

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

SPONSORED STORIES